Development of Data Analytic Framework and Therapy Device for Diabetic Management

Abstract

Diabetes Mellitus is a metabolic disorder collectively known as Type-1 newline(T1DM), Type-2 (T2DM), Gestational diabetes, and Monogenetic diabetes. Diagnosing newlinediabetes requires a regular quantification of blood glucose levels in the body which is newlinecarried out by invasive way of extracting blood from pathology reports and through home newlinemonitoring kits. Minimally invasive methods such as Continuous Glucose Monitoring newlinedevices (CGM) are associated with expensive high-maintenance sensors and transmitters newlinethat require to be changed along with the pods. These methods are painful, expensive, and newlineprone to infection if taken multiple times. The CGM generates an Ambulatory Glucose newlineProfile (AGP) report after a minimum period of 14 days of wearing the device. The report newlineexhibits blood glucose trends but it falls short in providing deeper insights with only Mean newlineGlucose (MG), Glycemic Variability (GV), Glucose Management Indicator (GMI), and newlineTime in Range (TIR). These metrics cannot reflect minute details, in identifying temporal newlinepatterns of glucose fluctuations, response to medication, persistence of glycemic peaks or newlinelows, reoccurrences of hyperglycemia, and hypoglycemia, and lack in ease of newlineinterpretability leading towards erroneous assessments. Fixed bolus insulin dosage is newlinesuggested by the doctor from the AGP report but lifestyle changes such as skipping a newlinemeal and the effect of physical activity may lead to hypoglycemia. Diabetic patients with newlineuncontrollable blood glucose develop Diabetic Peripheral Neuropathy (DPN). The newlinecurrently exercised solution for DPN is drugs or surgery which has the danger of newlineintervening with other cardiovascular diseases. Given the situation, in diagnosis, newlinetreatment optimization, and cure, a noninvasive system is required for diagnosing blood newlineglucose levels, enhancement of AGP report, and accurate insulin dosage prediction for newlinetreatment optimization, and in curing DPN newline